Suppr超能文献

膀胱过度活动症的个体化药物治疗。

Individualizing medical treatment of overactive bladder.

作者信息

Kuo Hann-Chorng

机构信息

Department of Urology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.

Department of Urology, School of Medicine, Tzu Chi University, Hualien, Taiwan.

出版信息

Tzu Chi Med J. 2018 Oct-Dec;30(4):195-199. doi: 10.4103/tcmj.tcmj_83_18.

Abstract

Overactive bladder (OAB) syndrome is highly prevalent in both men and women and might have negative impact on quality of life. Clinical trials of OAB usually highly select participants that may not reflect the real-world practice of OAB patients. The spectrum of OAB includes patients with idiopathic, neuropathic, with bladder outlet obstruction, and patients in elderly and medical comorbidities. Patients might have poor response to OAB medication or have adverse events after treatment. Therefore, treatment of OAB should be individualized to obtain therapeutic efficacy and avoid unacceptable adverse events. This article reviews the recently published literature and provides a guide for physicians to choose the appropriate treatment for different OAB patients.

摘要

膀胱过度活动症(OAB)综合征在男性和女性中都非常普遍,可能会对生活质量产生负面影响。OAB的临床试验通常对参与者进行高度筛选,这可能无法反映OAB患者的实际临床情况。OAB的范围包括特发性、神经性、伴有膀胱出口梗阻的患者,以及老年患者和患有合并症的患者。患者可能对OAB药物反应不佳,或在治疗后出现不良事件。因此,OAB的治疗应个体化,以获得治疗效果并避免不可接受的不良事件。本文回顾了最近发表的文献,并为医生为不同的OAB患者选择合适的治疗方法提供指导。

相似文献

1
Individualizing medical treatment of overactive bladder.
Tzu Chi Med J. 2018 Oct-Dec;30(4):195-199. doi: 10.4103/tcmj.tcmj_83_18.
2
Treatments for overactive bladder: focus on pharmacotherapy.
J Obstet Gynaecol Can. 2012 Nov;34(11):1092-1101. doi: 10.1016/S1701-2163(16)35440-8.
3
Botulinum toxin injections for adults with overactive bladder syndrome.
Cochrane Database Syst Rev. 2011 Dec 7(12):CD005493. doi: 10.1002/14651858.CD005493.pub3.
4
Current optimal pharmacologic therapies for overactive bladder.
Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2005-2019. doi: 10.1080/14656566.2023.2264183. Epub 2024 Jan 5.
5
Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia - Which medication to choose?
Tzu Chi Med J. 2023 Aug 22;35(4):312-316. doi: 10.4103/tcmj.tcmj_123_23. eCollection 2023 Oct-Dec.
8
Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management.
Neurourol Urodyn. 2018 Jan;37(1):83-88. doi: 10.1002/nau.23328. Epub 2017 Jun 20.
9
Bladder training for treating overactive bladder in adults.
Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2.
10
Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019.
Eur Urol Focus. 2019 May;5(3):329-336. doi: 10.1016/j.euf.2019.06.006. Epub 2019 Jun 21.

引用本文的文献

1
Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Investig Clin Urol. 2020 Feb;61(Suppl 1):S33-S42. doi: 10.4111/icu.2020.61.S1.S33. Epub 2019 Nov 13.

本文引用的文献

1
Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder.
Tzu Chi Med J. 2019 Apr 2;32(1):30-35. doi: 10.4103/tcmj.tcmj_226_18. eCollection 2020 Jan-Mar.
2
Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities.
Geriatr Gerontol Int. 2018 Sep;18(9):1330-1333. doi: 10.1111/ggi.13465. Epub 2018 Jun 21.
3
Efficacy and safety of mirabegron, a β -adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility.
Low Urin Tract Symptoms. 2019 Apr;11(2):O93-O97. doi: 10.1111/luts.12224. Epub 2018 Apr 26.
8
Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
Low Urin Tract Symptoms. 2017 Jan;9(1):27-32. doi: 10.1111/luts.12103. Epub 2015 Jul 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验